Below are some of the biopharma and health technology startups that have raised funding this week.

Athira Pharma
Headquarters: Seattle
Funding type: Series B
Amount raise: $85 million

Athira Pharma said Thursday that it had raised $85 million in a Series A funding round, led by Perceptive Advisors. New firms participating in the round included RTW Investments, Viking Global Investors, Venrock Healthcare Capital Partners, Franklin Templeton, Rock Springs Capital, LifeSci Venture Partners, Surveyor Capital, Highside Capital Management, Logos Capital, Janus Henderson Investors-managed funds, Sofinnova Investments, Avidity Partners. Existing investors Sahsen Ventures and Rick and Suzanne Kayne also took part.

The company plans to use the funding to support Phase II/III clinical development of NDX-1017, a drug it is developing for Alzheimer’s disease.

Nanox
Headquarters: Neve Ilan, Israel
Funding type: Equity investment
Amount raised: $20 million

A medical imaging technology company, Nanox said Thursday that it had raised $20 million in an equity investment from Seoul-based SK Telecom, already a current shareholder in the startup. The companies are also entering a partnership to increase accessibility to medical imaging to communities across socio-economic segments in South Korea and Vietnam, deploying 2,500 of Nanox’s systems that integrate its medical screening as a service model. Nanox also plans to set up a subsidiary in Korea that it will wholly own and that will be focused on scaling up production of its X-ray source semiconductor while using SK’s semiconductor expertise.

NodThera
Headquarters: Cambridge, U.K.
Funding type: Series B
Amount raised: $55 million

NodThera said Wednesday that it had raised $55 million in a Series B round, led by Novo Ventures. Other new investors include Cowen Healthcare Investments and Sanofi Ventures, while existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and Epidarex Capital also took part.

The company, which has offices in Cambridge as well as Seattle and Boston, is focused on developing drugs that target the NLRP3 inflammasome to treat diseases driven by chronic inflammation. Its lead candidate is NT-0167, which is currently in clinical development, going through a Phase I trial in healthy volunteers.

Ubie
Headquarters: Tokyo
Funding type: Series B
Amount raised: 2 billion yen ($18.7 million)

A medical technology company, Tokyo-based Ubie said Friday that it had raised 2 billion yen, or $18.7 million, in a Series B funding round from Suzuken, a pharmaceutical distributor based in Japan. The company plans to scale up Ubie for Hospital, its hospital software as a service product, and its consumer-facing artificial intelligence symptom checker, while also expanding research and development capabilities and hiring sales and engineering staff.

Photo: Feodora Chiosea, Getty Images



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here